Letter to the EditorComparative efficacy of vancomycin and teicoplanin in the treatment of hospitalised elderly patients with persistent meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia
References (5)
- et al.
Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial
Int J Antimicrob Agents
(1995) - et al.
Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan
J Antimicrob Chemother
(2010)
There are more references available in the full text version of this article.
Cited by (10)
Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation
2012, International Journal of Antimicrobial AgentsCitation Excerpt :Teicoplanin is a glycopeptide antibiotic that has been used to treat meticillin-resistant Staphylococcus aureus (MRSA) infections. Teicoplanin has similar efficacy to vancomycin and is associated with a lower adverse event rate than vancomycin [1,2]. Since teicoplanin has a long elimination half-life, an initial loading is required for rapid achievement of the optimal trough concentration.
Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia
2017, Expert Opinion on PharmacotherapyTeicoplanin
2017, Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh EditionChange of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis
2016, International Journal of Clinical Pharmacy
Copyright © 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.